Lpath Inc. expected to Report Fiscal Year 2009 Results on February 8, 2010. This event was calculated by Capital IQ (Created on November 13, 2009).

To present the recent clinical results from iSONEP(TM)

Lpath Inc. reported positive summary results of its single-dose Phase 1 clinical trial of iSONEP(TM) in wet-AMD patients. iSONEP met its primary endpoint of being well tolerated in all 15 patients at dose-levels ranging from 0.2 mg. to 1.8 mg. per intravitreal injection (three patients per dose level). No drug-related serious adverse events were reported in any of the patients. iSONEP also succeeded in meeting a key secondary endpoint in that a positive biological effect was observed in an encouraging number of patients. Most of these positive effects appear to be largely independent of the effects seen when wet-AMD patients undergo treatment with Lucentis(R) or with off-label use of Avastin(R), the predominant market leaders. Due to the small sample size, all biological effects described above and below can only be characterized as correlative at this time; no causal relationship has yet been established, statistically or otherwise.